THE SENSITIVITY TO CHANGE OF THE HAMILTON (HAMD) AND THE MONTGOMERY-ÅSBERG (MADRS) SCALES AS OUTCOME MEASURES IN ANTIDEPRESSANT TRIALS

Ballesteros J1, Perez V2, Puigdemont D3, Callado LF1, Alvarez E2, Artigas F3

1University of the Basque Country, UPV/EHU, Leioa, Vizcaya, Spain, 2Santa Creu i Sant Pau Hospital, Barcelona, Spain, 3Institut d’Investigacions Biomediques (CSIC-IDIBAPS), Barcelona, Spain

OBJECTIVES: To compare the sensitivity to change of the Hamilton Depression Rating Scale (HAMD) and the Montgomery-Åsberg Depression Rating Scale (MADRS) as outcome measures in antidepressant randomised controlled trials (RCTs).

METHODS: Data come from 2 RCTs (studies A and B) which assessed the efficacy of SSRIs plus pindolol or plus placebo in patients with Major Depression (MD). Study B recruited treatment resistant patients. Both studies included the HAMD and the MADRS as outcome measures. Study A did 10 follow-up measurements (since day 0 to day 42). Study B did 3 follow-up measurements (since day 0 to day 10). Standardised estimates for the change in the severity of depression since day 0 were calculated by a within-group effect size (dw) which accounted for the correlation between measurement times.

RESULTS: Study A showed a decreasing curvilinear pattern for the HAMD effect sizes (0, −0.55, −0.96, −1.25, −1.53, −1.97, −2.27, −2.15, −2.41, −2.57) which overlapped perfectly with the MADRS estimates (0, −0.56, −0.95, −1.23, −1.56, −1.88, −2.13, −2.17, −2.45, −2.64). Similar pattern was obtained in study B (HAMD: 0, −0.32, −0.62; MADRS: 0, −0.22, −0.52). Additionally, our estimates point to a reliable decrease of the severity of depression even since the first post-baseline measurement (study A, HAMD dw = −0.55 [95% CI = −0.73 to −0.37], MADRS dw = −0.56 [95% CI = −0.74 to −0.38]; study B, HAMD dw = −0.32 [95% CI = −0.52 to −0.11], MADRS dw = −0.22 [95% CI = −0.39 to −0.05]).

CONCLUSION: Contrary to common beliefs, the HAMD shows an indistinguishable pattern of change from the one obtained with the MADRS, either in common MD populations (study A), or in treatment resistant patients (study B). Also, reliable symptomatic changes seem to appear early on in the course of an antidepressant treatment.

DEVELOPING COST-EFFECTIVE FORMULARIES: IMPLICATIONS FOR NEW ATYPICAL ANTIPSYCHOTICS

Trakas K1, Diels JK2, Nicholl D3, Nuys G4

1Johnson & Johnson, Toronto, ON, Canada, 2Janssen Pharmaceutica, Beerse, Belgium, 3Johnson & Johnson, Raritan, NJ, USA

OBJECTIVES: Investigate the impact of paliperidone extended-release tablets (paliperidone ER), a newly available oral antipsychotic agent, on a health care formulary from a payer’s perspective using a hybrid cost-effectiveness/budget impact approach.

METHODS: An atypical antipsychotic formulary containing risperidone, olanzapine, aripiprazole, quetiapine and ziprasidone was compared to a formulary including the same 5 oral atypicals with the addition of paliperidone ER. Total medical costs and number of re-hospitalization stays were derived from Pharmetrics, a US outpatient insurance claims database with regionally representative coverage. Patients diagnosed with schizophrenia (ICD-9-CM code) in the year prior to initiating a new antipsychotic treatment with 1 full year retrospective and prospective data between January 2002-March 2005 were included. Markershare was based on IMS Health NDTI MAT ending June 2006. Paliperidone ER was assumed to attain 10% utilization, comparable to latest market entrant. Costs included all schizophrenia-related inpatient and outpatient costs, and re-hospitalization stays in the one year following initiation of treatment. Treatment effect was quantified by adjusting observed values for each atypical for potential confounders including patient characteristics, prior hospitalizations and co-morbidity using generalized gamma regression (GLM). The adjusted outcomes of risperidone and olanzapine were used to simulate the costs and effects of paliperidone ER. Sensitivity analyses were performed on key assumptions and nonparametric bootstrapping applied to observed data.

RESULTS: An estimated $121 per patient in total annual medical cost savings (95% CI: 35.11–206.27) could be achieved with the addition of paliperidone ER to the formulary. Assuming a hypothetical cohort of 10,000 patients, this translates into yearly savings of $1.2 million.

CONCLUSION: The addition of a new agent with similar efficacy and tolerability profile as paliperidone ER, may lead to a more cost-effective formulary.